Search

Displaying results 1691 - 1700 of 5449 in total
  1. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    It specifically replicates within tumor cells and causes lysis. It was approved by the FDA in 2015 under the market name Imlygic. … In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

    Synonyms: T Vec, T-Vec
  2. Drug

    SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer (B.1.351-B.1.1.7 strains)

    go.drugbank.com/drugs/DB18705
    Approved

    [L48902,L48907] Bimervax was issued marketing authorization in the EU in March 2023 for use as a booster dose in patients who have previously received an mRNA COVID-19 vaccine.[L48907] … [L48902] It is intended to elicit protection against Omicron XBB.1.5, one of the dominant circulating SARS-CoV-2 subvariants in 2023.

  3. Drug

    Vibrio cholerae CVD 103-HgR strain live antigen

    go.drugbank.com/drugs/DB14443
    ApprovedInvestigational

    [L39729] It is indicated for individuals aged two years and older.[L12801] … [A244489] The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera

  4. Drug

    Vorinostat

    go.drugbank.com/drugs/DB02546
    ApprovedInvestigational

    It is the first in a new class of agents known as histone deacetylase inhibitors. … Vorinostat (rINN) or suberoylanilide hydroxamic acid (SAHA), is a drug currently under investigation for the treatment of cutaneous T cell lymphoma (CTCL), a type of skin cancer, to be used when the disease

    Products: ZOLINZA®VORINOSTAT 100 MG CAPSULAS
  5. Drug

    Polatuzumab vedotin

    go.drugbank.com/drugs/DB12240
    ApprovedInvestigational

    Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells.

  6. Drug

    Dacarbazine

    go.drugbank.com/drugs/DB00851
    ApprovedInvestigational

    It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.

    Products: DACARBAZINA 200 MG, DACARBAZINA 100 MG
  7. Drug

    Difluprednate

    go.drugbank.com/drugs/DB06781
    ApprovedInvestigational

    It is indicated for treatment of endogenous anterior uveiti. … It is a butyrate ester of 6(α), 9(α)-difluoro prednisolone acetate. Difluprednate is abbreviated DFBA, or difluoroprednisolone butyrate acetate.

  8. Drug

    Sugemalimab

    go.drugbank.com/drugs/DB16641
    ApprovedInvestigational

    to treat T-cell lymphoma. … to have a better safety profile through avoiding unwanted attack of T-cells.

  9. Drug

    Iodine

    go.drugbank.com/drugs/DB05382
    ApprovedInvestigational

    Iodine is commonly used as an antiseptic for minor cuts and abrasions, preventing infections that may result from contaminated wounds. Additionally, iodine has been studied in the treatment of fibrocystic disease and breast cancer.

    Mixtures: Vitamines Et Mineraux Enfants 970, Duet DHA 400 ecProducts: Sky-Living Water MT Activition Liquid, Iodine Tab 3mg
  10. Drug

    Alglucosidase alfa

    go.drugbank.com/drugs/DB01272
    ApprovedInvestigational

    It is used for the treatment of Pompe disease (GAA deficiency) in infants and pediatric patients. … It is encoded by the most predominant of nine observed haplotypes of this gene. Aglucosidase alfa is produced by recombinant DNA technology in a Chinese hamster ovary cell line.